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Abstract The cellular resistance to the potent anticancer agent 
cis-diamminedichloroplatinnm(ll) (eisplatin) is thought to be 
mediated by multiple mechanisms. The technique of differential 
display of mRNAs was applied to various eisplatin-resistant cell 
lines and the corresponding parental sensitive human bladder, 
prostatic, and head and neck cancer cells in order to identify 
genes that underlie cisplatin resistance. Twenty-four clones were 
confirmed by Northern blot analysis to be expressed differen- 
tially between resistant and the corresponding sensitive cells. 
Partial DNA sequences of the eight clones that showed a 
threefold or greater increase in expression in either the resistant 
cells (seven clones) or sensitive cells (one clone) revealed that two 
were derived from the T-plastin gene and one from the tissue 
factor gene. The abundance of T-plastin mRNA in cisplatin- 
resistant T24/DDP10 cell was ~ 12 times that in the parental 
T24 cells. Transfection of T24/DDP10 cells with a vector 
encoding full-length T-plastin antisense RNA demonstrated that 
reduced T-plastin expression was associated with increased 
sensitivity to cisplatin. These results are consistent with the 
hypothesis that several mechanisms participate cooperatively in 
the acquisition of cisplatin resistance in human cancer. 
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transporter (cMOAT) [19]. Several of these mechanisms ap- 
pear to operate in individual resistant cell lines, with each 
mechanism alone accounting for only a small portion of total 
resistance. Thus, in contrast o the multidrug-resistance phe- 
notype conferred by expression of the human multidrug resist- 
ance 1 gene (MDR1) [20~23] or multidrug resistance-asso- 
ciated protein gene (MRP) [24,25], cisplatin resistance 
appears to require the simultaneous operation of multiple 
mechanisms. 
The techniques of subtractive hybridization [26] and differ- 
ential hybridization [27] have been used to isolate genes that 
are expressed differentially between two cell populations. 
However, these methods are associated with incomplete recov- 
ery of the candidate clone and require large quantities of 
mRNA, and are time consuming and labor intensive. The 
technique of differential display was recently developed to 
overcome these problems [28,29]. We have now used differen- 
tial display to isolate and characterize genes that are expressed 
differentially in cisplatin-resistant cell lines and their parental 
counterparts. 
2. Materials and methods 
I. Introduction 
The potent anticancer agent cis-diamminedichloroplati- 
num(II) (cisplatin) is widely used for treating a variety of 
malignant umors, including those of the testes, head and 
neck, esophagus, mall cell lung, ovary, and bladder [1]. How- 
ever, clinical use of this drug for long periods is often limited 
because of the appearance of cisplatin-resistant tumor cells [2]. 
Cisplatin resistance in such cells appears to be mediated 
through various mechanisms, including inactivation of cispla- 
tin by thiol-containing molecules uch as glutathione [3-6] and 
metallothionein [7,8], increased DNA repair [9-11], decreased 
drug accumulation [12-15], increased expression of DNA to- 
poisomerase I [16], and increased abundance of thioredoxin 
[17]. Moreover, it has been proposed that cisplatin could be 
transported out of the cell after conjugation with glutathione 
[18] and a putative corresponding pump has been isolated and 
identified as human canalicular multispecific organic anion 
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2.1. Cell culture and cell lines 
Cisplatin-resistant cell lines were derived from various drug-sensi- 
tive parental counterparts a described previously ([5,15-17], respec- 
tively): T24/DDP5, T24/DDP7, and T24/DDP10 from human bladder 
cancer T24 cells [16]; P/CDP5 from human prostatic ancer PC-3 cells 
[5,15]; KCP-4 from human head and neck cancer KB cells [13]; and 
KK47/CB60 from human bladder cancer KK47 cells [17] (Table 1). 
These cell lines were cultured at 37°C under a humidified atmosphere 
of 5% CO2 in Eagle's minimum essential medium (Nissui Seiyaku, 
Tokyo, Japan) containing 10% fetal bovine serum (Sera-lab, Sussex, 
UK), Bactopeptone (1 mg/ml) (Difco, Detroit, MI, USA), glutamine 
(0.292 mg/ml), kanamycin (100 mg/ml), and penicillin (100 U/ml). 
2.2. Differential display 
Differential display was performed as described [29] with the use of 
an RNAmap kit (GenHunter, Brookline, MA, USA). Briefly, purified 
polyadenylated RNA (0.02 lag) was reverse transcribed with 1 laM of 
either T12MG, Ta2MA, T12MT or T12MC oligonucleotide (where M is 
3-fold degenerate for G, A and C) as primer. The solution was heated 
to 65°C for 5 min and cooled to 37°C for 10 min, and then 200 units 
of reverse transcriptase was added. After incubation at 37°C for 1 h, 
the mixture was heated to 95°C for 5 min and stand on ice immedi- 
ately. PCR was then performed as follows. Reaction mixtures con- 
tained 0.1 volume of reverse transcription reaction, I x PCR buffer, 20 
laM each dGTP, dATP, dTTP and dCTP, 4 laCi of [32p]dCTP, 1 laM 
of the respective T12 MN oligonucleotide (M = G, C or A; N = G, A, T 
or C), 0.2 laM specific arbitrary 10-mer, and 10 units of AmpliTaq 
DNA polymerase. Conditions of amplification were 40 cycles of 94°C 
for 30 s, 40°C for 2 min and 72°C for 30 s; and 1 cycle of 72°C for 
5 min. 3.5 I.tl of sample was mixed with 2 lal of loading dye, heated at 
80°C for 2 min immediately before loading onto a 6% DNA sequenc- 
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ing gel. Gels were run for about 3 h at 60 W constant power, dried 
and exposed directly to X-ray film overnight at room temperature. 
Recovery and reamplification of cDNA fragments from dried DNA 
sequencing gels were also performed as described previously [29]. 
2.3. Northern blot analysis 
Total RNA was isolated by single-step acid guanidinium thiocya- 
nate-phenol-chloroform extraction, as previously described [30], frac- 
tionated on a 1% agarose gel containing 2.2 M formaldehyde, and 
transferred to a Hybond N + membrane (Amersham, Buckingham- 
shire, UK). RNA was cross-linked to the membrane by ultraviolet 
irradiation. 32p-Labeled DNA probes were prepared by random prim- 
ing [31] with a DNA labeling kit (Amersham) and [c~-32P]dCTP (Du- 
pont Biotechnology Systems, Boston, MA, USA), and were derived 
from the inserts of differential display (dd) clones propagated in the 
pGem-T vector (Promega, Madison, WI, USA) or from PCR prod- 
ucts. After hybridization, the amount of mRNAs corresponding to the 
dd clones was quantitated with a BAS2000 Bioimaging Analyzer 
(Fuji, Tokyo, Japan). 
2.4. DNA sequenc&g 
dd clones were purified with QIAGEN-tip 20 (QIAGEN, Chats- 
worth, CA). Chain elongation and termination were performed with 
a DyeDeoxy Terminator Cycle Sequencing kit, and nucleotide se- 
quencing was performed with a DNA sequencer (model 373A; 
Applied Biosystems, Foster City, CA). 
2.5. &olation of fulMength T-plastin cDNA 
Human T-plastin cDNA was generated by reverse transcription and 
PCR with mRNA extracted from the T24/DDP10 cell line. Reverse 
transcription was performed with a mixture containing 5 /ag of 
mRNA, 20 gmol of random hexanucleotides, 200 gmol of each deoxy- 
nucleoside triphosphate, 50 mM Tris-HC1 (pH 8.3), 10 mM MgCI2, 
50 mM KCI, and 40 U of reverse transcriptase. The mixture was 
incubated at 42°C for 1 h, heated at 95°C for 10 min, and treated 
with 10 mg of DNase-free RNase. The resulting cDNA was precipi- 
tated and resuspended in 50/.tl of water, and 10 [ul of the resulting 
suspension were subjected to amplification with two different sets of 
primers, yielding two overlapping cDNA fragments encoding full- 
length human T-plastin. In the first amplification, the sense primer 
(5'-ATTCCGAGGTGCAGAAGTTG-3') corresponded to nucleo- 
tides 5 24 [32] and the reverse primer (5'-CTATCCGTGGTT- 
CACCTTCC-3') was complementary to nucleotides 1032-1051 of hu- 
man T-plastin cDNA [37]. In the second amplification, the sense 
primer (5'-AGCAGGAATGAAGCCTTGG-3') corresponded to nu- 
cleotides 822-840 and the reverse primer (5'-TAGCTGACCTGC- 
GAATCATG-3') was complementary to nucleotides 2019-2038 of 
human T-plastin cDNA. Amplification was performed with a Per- 
kin-Elmer (Norwalk, CT) thermal cycler for 25 cycles of 94°C for 
1 min, 54°C for 1 min, and 72°C for 1 min. The products of the first 
and second amplifications were digested with Pstl alone or PstI and 
EcoRI, respectively, and the resulting fragments were ligated via the 
Pstl site and incorporated into the PstI and EcoRI sites of the pMOS- 
Blue plasmid (Amersham). The full-length human T-plastin cDNA 
sequence was checked by double-strand sequencing with the Dye- 
Deoxy Terminator Cycle Sequencing kit and a DNA sequencer (mod- 
el 373A, Applied Biosystems); no discrepancies were detected. 
2.6. Construction of and transfection with ant&ense T-plast& plasmid 
The T-plastin cDNA was isolated and purified from the pMOSBlue 
plasmid after digestion with BamHI and NdeI, after nucleotide addi- 
tion with the Klenow enzyme and ligation to XbaI linkers, the cDNA 
was cloned into XbaI sites of the expression vector pRC/CMV (Invi- 
trogen, San Diego, CA) in the antisense orientation. The plasmid was 
then transfected into T24/DDP10 cells and stable transfectants were 
isolated as described previously [6,17]. 
2. 7. Immunoblot analysis of T-plastin 
Whole-cell extracts from each cell line were fractionated by sodium 
dodecyl sulfate-polyacrylamide gel electrophoresis on 10% gels, and 
separated proteins were transferred to a nylon membrane in 25 mM 
Tris-HCl (pH 8.3), 192 mM glycine, and 20% methanol for 1 h at 300 
mA [6,17]. The filters were incubated with 5% nonfat milk in Tris- 
buffered saline for 30 min at room temperature, and then with anti- 
bodies to plastin for 40 min. After washing twice with Tris-buffered 
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saline, the filters were incubated with horseradish peroxidase-conju- 
gated secondary antibodies and immune complexes were detected by 
enhanced chemiluminescence (ECL detection kit; Amersham). We 
used rabbit polyclonal antibodies that recognize T-plastin or L-plastin 
specifically [33], as well as antibodies to T-plastin [34] (kindly pro- 
vided by M. Arpin) that recognize both T- and L-plastin (T. Hisano 
and M. Wada, unpublished ata). 
2.8. Cell survival assay by colony formation 
Cells (400-1000) were seeded in 35-mm dishes, and incubated at 
37°C in the absence of drug for 18 h and then in the presence of 
cisplatin for an additional 6 days; the number of colonies was then 
counted after Giemsa staining, as described previously [17]. The plat- 
ing efficiency for T24 and T24/DDP10 cells transfected with the ex- 
pression vector pRC/CMV alone [T24(vector), T24/DDP10(vector)-I 
and -2, respectively] or for T24/DDP10 cells transfected with the vec- 
tor containing T-plastin eDNA in the antisense orientation [T24/ 
DDPI0(AS)-I, -2 and -3] were 67%, 50%,, 52%, 48%, 54% and 51%, 
respectively. 
3. Results 
Various cisplatin-resistant cell lines and their sensitive par- 
ental counterparts (Table 1) were subjected to differential 
mRNA display analysis. A total of 15 arbitrary 10-nucleotide 
PCR primers (15 for PC3, P/CDP5, T24, T24/DDP10, KK47 
and KK47/CB60, and 4 for KB and KCP-4, respectively) were 
used in combinat ion with two T12MN reverse transcription 
primers, T12MG and T12MC, chosen because they yielded 
the largest numbers of display bands. Each differential display 
lane yielded ~ 150-200 discrete bands, allowing evaluation of 
>6000 RNA species, or 30-60% of the estimated i0000-  
20000 cellular mRNAs  [35], for each comparison. From 150 
differentially displayed bands on sequencing els, we recov- 
ered 107 clones, 64 of which hybridized to cellular RNAs 
on Northern blot analysis. Twenty-four of these clones were 
confirmed to be expressed ifferentially between drug-resistant 
cell lines and their sensitive counterparts, eight of which (des- 
Table 1 
Human cancer cell lines resistant to cisplatin 












Bladder cancer cell b 
Increased expression of topoisomerase I, 
decreased cisplatin accumulation 
Increased expression of topoisomerase I, 
decreased cisplatin accumulation 
Increased expression of topoisomerase I, 
decreased cisplatin accumulation 
Prostatic ancer cell b 
Decreased cisplatin accumulation, 
increased thioredoxin level 
Head and neck cancer cell b 
Decreased cisplatin accumulation, 
increased thioredoxin level 
Bladder cancer cell ° 
Increased metallothionein expression, no 
reduced cisplatin accumulation 
~Relative resistance to cisplatin was calculated as IC50 of drug-resist- 
ant cell line divided by IC50 of each parental cell line, ICs0 being the 
dose required to reduced the initial survival fraction to 50%. 
bThe isolation and properties of cisplatin-resistant cell lines derived 
from their drug-sensitive counterparts have been described previously 
([16,15,13,6], respectively). 
"S. Kotoh, S. Naito and J. Kumazawa, unpublished ata. 
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probe dd21 dd39 dd47 dd59 dd69 dd72 dd78 dd87 
Fig. 1. Northern blot analysis of total RNA from the indicated cell lines with eight differentially expressed eDNA fragments as probes. The po- 
sitions of 28S and 18S rRNA are indicated. Lower panels show ethidium bromide staining of rRNA in the gel prior to blotting. 
ignated d21, dd39, dd47, dd59, dd69, dd72, dd78, and dd87) 
showed a threefold or greater increase in expression in either 
the resistant cell lines (seven clones) or their sensitive counter- 
parts (dd47) by Northern blot analysis (Fig. 1, Table 2). 
Database searches revealed that clones dd72 and dd87 were 
derived from the human T-plastin gene, dd78 from the human 
tissue factor gene, and dd21 from the human mitochondrial 
DNA D-loop region, clone dd59 showed 60% identify to the 
Escherichia coli N-acetylglucosamine d aminase gene [36], 
clones dd47 and dd69 were identical to human cDNAs gen- 
erated by random sequencing projects, and clone dd39 showed 
no homology to previously characterized sequences. 
The sequences of dd72 and dd78 are aligned with those of 
human T-plastin and human tissue factor genes in Fig. 2. The 
only sequence differences corresponded to the primer regions 
of the dd clones, as might be expected from the low-stringency 
conditions of PCR at the early steps of differential display. 
The DNA sequence of clone dd72 corresponded not to the 3' 
end of the eDNA but to an internal coding region, with the 
poly(T) primer corresponding to an internal A-rich region and 
not to the 3' poly(A) tail (Fig. 2). The size of the mRNA (3.4 
kb) corresponding to clone dd72 as determined by Northern 
blot analysis (Fig. 1) is also consistent with that previously 
determined for T-plastin mRNA [37]. 
The amount of T-plastin mRNA in cisplatin-resistant T24/ 
DDP10 cells is ,~ 12 times that in the parental T24 cells (Fig. 
1, Table 2). The abundance of T-plastin mRNA was also 
increased in the cisplatin-resistant T24/DDP5, T24/DDP7, 
KCP-4, and P/CDP5 cell lines relative to that in the corre- 
sponding parental cells (Fig. 3); such increase in T-plastin 
mRNA was not apparent in cisplatin-resistant KK47/CB60 
cells compared to the sensitive parental KK47 cells. Northern 
blot analysis with a dd87 probe, the nucleotide sequence of 
which was also identical to that of the T-plastin gene, gave 
results (data not shown) identical to those obtained with the 
dd72 probe (Fig. 3). 
We investigated the expression of T-plastin protein by im- 
munoblot analysis. Rabbit polyclonal antibodies generated 
against T-plastin but which recognize both T- and L-plastin 
[34] reacted with a 68-kDa protein in T24/DDP10 and T24 
cells solubilized with SDS; the intensity of the immunoreac- 
tive band in the cisplatin-resistant cells was ,~ 5 times that in 
the parental cells (data not shown) (T. Hisano and M. Wada, 
unpublished ata). The amounts of T- and L-plastin were 
then determined separately with antibodies pecific for each 
of these proteins [33]. The intensities of both the T- and L- 
plastin bands in T24/DDP10 cells were approximately three 
times those of the corresponding bands in T24 cells (Fig. 4A). 
To evaluate whether overexpression of T-plastin in T24/ 
DDP10 cells is functionally associated with cisplatin resist- 
ance, we generated T24/DDP10 cell lines that stably ex- 
pressed full-length T-plastin antisense RNA. In two G418- 
resistant cell lines, T24/DDP10(AS)-I and -2, the amounts 
of T-plastin was reduced to 30%, respectively; in another 
G418-resistant cell line, T24/DDP10/AS-3, the amounts of 
T- and L-plastin were similar to those in mock transfectant 
of T24/DDP10 cells, T24/DDP10(vector)-i and -2 (Fig. 4A). 
The dose-response relations for the cytotoxic effect of cisplatin 
on T24/DDP10(AS)-l, -2 and -3 cells were determined by 
colony formation assays (Fig. 4C). T241DDP10(AS)-I and 
-2 cells were approximately twice as sensitive to the cytotoxic 
effect of cisplatin as were T24/DDP10(vector)-l, -2 or T24/ 
DDP10(AS)-3 cells. In contrast, T24/DDP10(AS)-I and -2 
ceils showed similar sensitivities to anticancer agents that tar- 
104 T. Hisano et al./FEBS Letters 397 (1996) 101-107 
A 
dd72 
T -p las t in  
dd72 
T -p las t in  
dd72 
T -p las t in  
dd72 
T -p las t in  
dd72 
T -p las t in  
dd72 
T -p las t in :  
dd72 
T -p las t ln :  
dd72 
T -p las tmn:  
dd72 
T -p las t ln :  
dd72 
T -p las t ln :  
dd72 
T -p las t ln :  
dd72 


























GT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  207 
TTGTTAACTGGATAAACAAAGCTTTGGAAAATGATCCTGATTGTAGACAT I00 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  257 
GTTATACCAATGAACCCTAACACCGATGACCTGTTCAAAGCTGTTGGTGA 150 




. . . . . . . . . . . . . . . . . . . . . . . .  407 
AACTTGAACTTGGCACTGAACTCTGCTTCTGCCATTGGGTGTCATGTTGT 300 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  457 
GAACATTGGTGCAGAAGATTTGAGGGCTGGGAAACCTCATCTGGTTTTGG 350 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  507 
GACTGTTTTGGGACTAGCTTTGGCAGATCATTAAGATCGGTTTGTTCGCT 400 
. . . . . . . . . . . . . . . . . .  557 
GACATTGAATTAAGCAGGAATGCAGGAATGAAGCCTTGGCTGCTTTACTC 450 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  607 
CGAGATGGTGAGACTTTGGAGGAACTTATGAAATTGTCTCCAGAAGAGCT 500 
. . . . . . . . . . . . . . . . . . . . . . .  657 
TCTGCTTAGATGGGCAAACTTTCATTTGGAAAACTCGGGCTGGCAAAAAA 550 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  707 
AAAAAAA 557 










1 Aq~TGACCQTAGAAGATGAACGGACTTTAGTCAGAAGGAACAACACTTTC 50 
598 -T . . . . . . . . . . . . . . . . . .  591 
51 CTAAGCCTCCGGGATGTTTTTGGCAAGGACTTAATTTATACACTTTATTA I00 
648 . . . . . .  641 
I01 GAAAGAAAACAGCCAAAACAAACACTAATGAGTTTTTGATTGATGTGGAA 150 
698 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  T 691 
151 AAAAAAAAAA 160 
748 - - -GG-G- - -  757 
Fig. 2. Nucleotide sequences of clones dd72 (A) and dd78 (B) aligned with the corresponding regions of human T-plastin and human tissue fac- 
tor (TF) genes, respectively. Dashes represent identical residues, flanking primer sequences are underlined, and numbering of T-plastin [37] and 
tissue factor [38] sequences is as previously described. 
get topoisomerases I and II (etoposide and camptothecin, re- 
spectively) as T24/DDP10(vector)-l, 2 and T24/DDP10(AS)- 
3 cells (data not shown). 
4. Discussion 
We have shown that the T-plastin gene is overexpressed in 
cisplatin-resistant cell lines derived from T24 bladder cancer, 
PC-3 prostatic ancer, and KB head and neck cancer cells. In 
addition, the results of our antisense xperiments indicated a
functional relation between the extent of T-plastin expression 
and the extent of cisplatin resistance. The higher cisplatin 
resistance of T24/DDP10(AS)-I and -2 cells relative to 
T24(vector) cells suggests either a role for other mechanisms, 
such as overexpression f topoisomerase I [16], in the resist- 
ance phenotype of T24/DDP10 cells, or inadequate suppres- 
sion of T-plastin function by antisense xperiments. Both 
plastins and fimbrins, families of actin-binding proteins, are 
differentially expressed in normal tissues and malignant u- 
mors [32,37]. The L isoform of plastin is expressed in hema- 
topoietic cells and tumor cells of nonhematopoietic origin, 
whereas the T isoform is present in all other normal cells 
[39]. Arpin et al. [33] showed that overproduction of T- and 
L-plastins induces cell rounding and a concomitant reorgani- 
zation of actin fibers in both fibroblast-like and polarized 
epithelial cell lines. T-plastin induces hape changes in micro- 
villi and remains associated with microvillar actin filaments, 
whereas L-plastin remains associated with microfilaments, 
suggesting functional differences between L- and T-plastin iso- 
forms [34]. 
Plastin-associated actin might affect the intracellular distri- 
bution of cisplatin. Bauman et al. [40] showed that mitoxan- 
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GAPDH 
Fig. 3. Northern blot analysis of total RNA from the indicated cisplatin-resistant d parental cell lines with a dd72(T-plastin) probe. The 
bands corresponding to T-plastin and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA, the latter of which was used as a control, 
are indicated. 
tron binds to cytokeratins, which are components of inter- 
mediate filaments, and that forced expression of cytokeratins 
8 and 18 increased mitoxantron resistance without affecting 
intracellular drug accumulation, suggesting that the cytoker- 
atin network may influence the intracellular drug distribution 
in such a manner that the nuclear targets of the drug are 
spared. Thus, cisplatin may be similarly trapped in the cyto- 
plasm by plastin-associated actin. Alternatively, cisplatin- 
mediated binding of actin to DNA [41] may be decreased by 
overexpression f plastin. Moreover, reduction of intracellular 
accumulation of cisplatin might induce reduced cisplatin- 
DNA adduct in P/CDP5 cells, because difference in the 
amount of DNA interstrand cross-links between P/CDP5 
and its parental strain PC3 are less than difference of cisplatin 
accumulation between the two cell lines ([15] and see below). 
Alternatively a reorganization of actin filaments associated 
with plastin overexpression might affect the expression of 
genes important in cisplatin resistance or DNA repair. Actin 
has been shown to modulate DNA replication, transcription, 
and repair [.4244]. 
Overexpression of plastin might also affect the activity of 
the transporter that mediates cisplatin efflux. Recently, it has 
been proposed that cisplatin could be transported out of the 
cell after conjugated with glutathione [18] and a putative cor- 
responding pump has been isolated and identified as human 
cMOAT [19]. Overexpression of the human cMOAT mRNA 
was observed in all three cisplatin-resistant cell lines with in- 
creased expression of T-plastin, T24/DDP10, P/CDP5 and 
KCP-4, but not in KK47/CB60 without increased expression 
of T-plastin [19]. The actin-based cytoskeleton regulates the 
activity of many ion channels and transport proteins [45]. For 
example, phallacidin, a mushroom toxin that stabilizes actin, 
inhibits cyclic AMP-stimulated CI- secretion thought to be 
mediated by the cystic fibrosis transmembrane conductance 
regulator (CFTR) CI- channel in a human colonic epithelial 
cell line [46]. Moreover, CFTR possesses three domains that 
are homologous to the actin-binding domains of gelsolin and 
villin, and cytochalasin D increases CFTR-mediated ATP cur- 
rents [47,48]. On the other hand, Christen et al. [49] detected a
difference in microtubule arrangements between a cisplatin- 
resistant cell line and the corresponding parental human ovar- 
ian cancer cells. Treatment of human ovarian cancer cells with 
forskolin, an activator of adenylate cyclase, or with 3-isobu- 
tyl-l-methylxanthine, a phosphodiesterase inhibitor, induced 
phosphorylation of ~-tubulin and increased intracellular accu- 
mulation of cisplatin [49]. We observed increased expression 
of T-plastin in cisplatin-resistant cell lines (derived from par- 
ental T24, PC-3, and KB cells) that show decreased intracel- 
lular accumulation of the drug [13,15,16]. However, T-plastin 
expression was not increased in cisplatin-resistant KK47/CB60 
cells, which do not show decreased cisplatin accumulation 
relative to the parental KK47 cells [17]. Thus, overexpression 
Table 2 
Characteristics of dd clones expressed ifferentially between cisplatin resistant and sensitive cell line 
dd PCR product Parental: resistant Relative mRNA mRNA Identity 
Clone size (bp) line a increase b size (kb) c 
dd21 150 PC3:P/CDP5 3.0 + 0.62 4.2 
dd39 31)0  T24:T24/DDP10 4.8 + 0.72 4.0 
dd47 200 KK47: CB60 0.3 + 0.02 2.5 
dd59 300 PC3 : P/CDP5 3.1 + 0.79 3.3 
dd69 400 PC3 : P/CDP5 16.8 + 1.08 3.5 
dd72 550 T24:T24/DDP10 12.1 + 1.41 3.7 
dd78 160 T24:T24/DDP10 5.8 + 1.59 3.4 
dd87 550 T24:T24/DDP10 11.9 + 0.79 3.7 
Human mitochondrial D loop region (100%) 
None 
gb: T68184 liver cDNA library (100%) d
E. eoli acetylglucosamine deaminase-like 
gb: H14661 infant brain eDNA library (100%) c 
T-plastin (100%) 
Human tissue factor (100%) 
T-plastin (100%) 
~Parental cell lines and their resistant counterparts from which dd clone was isolated. 
6Relative mRNA increase for each clone was determined by Northern blot analysis (Fig. 1); those of each parental cell line were normalized as 1.0. 
The relative values were the average of more than two independent assays, and the two analyses showed 20% variation from the average. S.D. is 
given after +. 
CApproximate mRNA sizes were calculated from Fig. 1 by using ribosomal RNA as a standard. 
dThese sequences have been deposited in Genbank by the WASH U-Merk random sequencing project without functional information. 
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Fig. 4. A: Immunoblot analysis of extracts of T24 and T24/DDP10 
cells transfected with the expression vector pRC/CMV alone 
[T24(vector), T24/DDP10(vector)-I and -2, respectively] or of T24/ 
DDP10 cells transfected with the vector containing T-plastin cDNA 
in the antisense orientation [T24/DDP10(AS)-l, -2 and -3]. Blots 
were probed with antibodies pecific for T- or L-plastin as indi- 
cated. Two nonspecific bands, the intensities of which are identical 
in all six cell lines, are apparent below the T-plastin band. B: Coo- 
massie blue-stained gel before blotting demonstrating equal sample 
loading among lanes. Molecular size standards are indicated in kilo- 
daltons. C: Dose-response r lations for the cytotoxic effect of cispla- 
tin on T24(vector) (×), T24/DDP10(vector)-I (E3), -2 (/x), T24/ 
DDP10(AS)-I (A), -2 (11) and -3 (0) cells. Data are means of tripli- 
cate dishes, with 100% corresponding to the colony number for 
each cell line incubated in the absence of drug. Bars, S.D. 
of T-plastin might contribute to a decreased cellular accumu- 
lation of cisplatin through modulation of the transporter ac- 
tivity. 
We also showed that the abundance of human tissue factor 
mRNA in T24/DDP10 cells was approximately six times that 
in the parental T24 cells. Both exogenously added and endo- 
genously generated oxygen free radicals induce tissue factor 
expression in vascular endothelial cells [50]. Cisplatin gener- 
ates oxygen free radicals [51], and tissue factor might thus be 
induced by treatment with cisplatin. Selection for drug resist- 
ance to cisplatin in bladder cancer cells may generate oxygen 
free radicals, and thereby result in constitutive xpression of 
tissue factor. 
Genes encoding topoisomerase I and thioredoxin which are 
known to be overexpressed in P/CDP5 and/or T24/DDP10 
[16,17], respectively were not isolated in this study. This is 
because either we used limited number of primer sets and 
estimated coverage was 3~60% of total mRNA species ex- 
pressed, or such genes did not match with arbitrary primers 
used under even low stringent conditions. Nucleotide se- 
quence alignment analysis between each primers used in this 
study and either topoisomerase I or thioredoxin revealed that 
expected size of PCR products in differential display was 
either smaller than 100 bp or larger than 1 kb, which range 
DNA could not be recovered from in our system. It would be 
necessary to use more primer sets for complete coverage of 
every mRNA species. With all these limitations, the differen- 
tial gene expression detected in our study between cisplatin- 
resistant and parental cell lines is consistent with the notion 
that resistance to this drug is mediated by multiple mecha- 
nisms. Further investigations are required to elucidate the 
roles of these differentially expressed genes in development 
of the resistance phenotype. 
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